Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

Hemocompatibility of biomaterials in contact with the blood of patients is a prerequisite for
the short-and long-term applications of medical devices such as cardiovascular stents …

Postoperative neurological disorders, including postoperative delirium (POD), postoperative
cognitive dysfunction (POCD), postoperative covert ischemic stroke, and hemorrhagic …

Cardiovascular diseases (CVDs) have been the leading cause of death for over 20 years.
The main causative factors are believed to be high cholesterol, obesity, smoking, diabetes …

Abstract Purpose of Review Stroke is a leading cause of death and disability worldwide. The
annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

The anticoagulation field is experiencing a renaissance that began with regulatory approval
of the direct thrombin inhibitor dabigatran, a direct oral anticoagulant (DOAC), in 2010. The …

Anticoagulation is key to the treatment/prevention of thromboembolic events. The primary
complication of anticoagulation is serious or life-threatening hemorrhage, which may …

Background: Review of clinical data on andexanet alfa for the reversal of factor Xa (FXa)
inhibitor associated anticoagulation. Data sources: In the present review, we identified …

The conjunction of atrial fibrillation (AF) and venous thromboembolism (VTE) is common in
clinical practice. Over the last 2 decades, a significant number of articles (2500) have been …